A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma

Abstract

BackgroundPrecision medicine approaches are ideally suited for rare tumors where comprehensive characterization may have diagnostic, prognostic, and therapeutic value. We describe the clinical case and molecular characterization of an adolescent with metastatic poorly differentiated carcinoma (PDC). Given the rarity and poor prognosis associated with PDC in children, we utilized genomic analysis and preclinical models to validate oncogenic drivers and identify molecular vulnerabilities.MethodsWe utilized whole exome sequencing (WES) and transcriptome analysis to identify germline and somatic alterations in the patient’s tumor. In silico and in vitro studies were used to determine the functional consequences of genomic alterations. Primary tumor was used to generate a patient-derived xenograft (PDX) model, which was used for in vivo assessment of predicted therapeutic options.ResultsWES revealed a novel germline frameshift variant (p.E1554fs) in APC, establishing a diagnosis of Gardner syndrome, along with a somatic nonsense (p.R790*) APC mutation in the tumor. Somatic mutations in TP53, MAX, BRAF, ROS1, and RPTOR were also identified and transcriptome and immunohistochemical analyses suggested hyperactivation of the Wnt/ß-catenin and AKT/mTOR pathways. In silico and biochemical assays demonstrated that the MAX p.R60Q and BRAF p.K483E mutations were activating mutations, whereas the ROS1 and RPTOR mutations were of lower utility for therapeutic targeting. Utilizing a patient-specific PDX model, we demonstrated in vivo activity of mTOR inhibition with temsirolimus and partial response to inhibition of MEK.ConclusionsThis clinical case illustrates the depth of investigation necessary to fully characterize the functional significance of the breadth of alterations identified through genomic analysis.Electronic supplementary materialThe online version of this article (doi:10.1186/s13073-016-0366-0) contains supplementary material, which is available to authorized users.

Identification of Differentially Expressed Genes between Original Breast Cancer and Xenograft Using Machine Learning Algorithms

“…To identify a cure for breast cancer, researchers have applied five levels of research, namely, molecular, cellular, histopathological, animal model, and clinical levels [ 4 ]. Among these levels, the animal model level not only confirms the conclusion obtained from studies on the other levels as an integrated creature but also lays the foundation for further clinical studies [ 5 , 6 ]. In studies on this level, mice are a typical and widely used species because of their high degree of genetic similarity to human beings and simple cultivation requirements.…”

Ex vivo assessment of targeted therapies in a rare metastatic epithelial–myoepithelial carcinoma

“…Mutations in PI3KR1 gene coding for p85α, the regulatory subunit of PI3K, may also convert sensitivity to targeted PI3K and downstream effector inhibition including AKT and mTOR [27] . Mutations of RPTOR are associated with in vivo activity of mTOR inhibition and partial response to inhibition of MEK [28] . Based on these and the ex vivo results and after unsuccessful search of available clinical trials for mTOR-MEK combination therapies, the patient was started on Everolimus mTOR inhibitor therapy at a daily 10 mg dose adopted from renal cell cancer indication.…”

Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes

“…Predominant questions driving both oncologists and cancer geneticists are under what circumstances information generated from genomic testing can be used to inform therapeutics or impact plans for risk reduction and prevention strategies (Kauff et al, 2002; Lima et al, 2018; Villani et al, 2016). Currently, major cancer centers perform parallel sequencing of tumor and matched normal (germline or constitutional) DNA, which can simultaneously reveal information about therapeutic options and cancer predisposition (Dela Cruz et al, 2016; Mody et al, 2015; Oberg et al, 2016; Parsons et al, 2016; Walsh et al, 2014). Two large-scale studies, one pediatric and one adult, have used similar methodology integrating somatic data to augment germline variant calling (Huang et al, 2018; Zhang et al, 2015).…”